Literature DB >> 19328547

Laromustine: the return of alkylators to non-myeloablative therapy of AML.

Francis J Giles.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19328547     DOI： 10.1016/j.leukres.2009.02.002

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  3 in total

1.  Quantitative relationship between guanine O(6)-alkyl lesions produced by Onrigin™ and tumor resistance by O(6)-alkylguanine-DNA alkyltransferase.

Authors:  Kimiko Ishiguro; Yong-Lian Zhu; Krishnamurthy Shyam; Philip G Penketh; Raymond P Baumann; Alan C Sartorelli
Journal:  Biochem Pharmacol       Date:  2010-07-21       Impact factor: 5.858

2.  KS900: A hypoxia-directed, reductively activated methylating antitumor prodrug that selectively ablates O(6)-alkylguanine-DNA alkyltransferase in neoplastic cells.

Authors:  Raymond P Baumann; Kimiko Ishiguro; Philip G Penketh; Krishnamurthy Shyam; Rui Zhu; Alan C Sartorelli
Journal:  Biochem Pharmacol       Date:  2011-03-17       Impact factor: 5.858

3.  Reductive activation of the prodrug 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine (KS119) selectively occurs in oxygen-deficient cells and overcomes O(6)-alkylguanine-DNA alkyltransferase mediated KS119 tumor cell resistance.

Authors:  Raymond P Baumann; Philip G Penketh; Kimiko Ishiguro; Krishnamurthy Shyam; Yong L Zhu; Alan C Sartorelli
Journal:  Biochem Pharmacol       Date:  2009-12-11       Impact factor: 5.858
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.